Psychological impact of endometrial monitoring in tamoxifen-treated postmenopausal breast cancer patients.
In view of the higher incidence of endometrial pathology in tamoxifen-treated breast cancer patients, it has been recommended that endometrial surveillance be performed on these women by means of transvaginal sonography. Our study investigated how breast cancer patients experience the endometrial surveillance and which personality factors influence this experience. We also studied compliance with the recommended examination. Fifty-three consecutive asymptomatic postmenopausal breast cancer patients who had taken tamoxifen for at least 6 months were included. Our results show that 23% of the women felt very anxious just before the examination. One woman in five evaluated the procedure as annoying, unpleasant, invasive and awkward, but only 3% found it really unacceptable. Difficulties in coping with mastectomy as well as anxiety negatively affected the experience of the examination. One in six women were doubtful about their ability to comply with such an examination in the future. Women who have difficulties in coming to terms with the mastectomy, anxious women, and women with a low tolerance towards common medical procedures are at especial risk of becoming dropouts. Suggestions are made for developing strategies that might improve these women's compliance.
Demyttenaere
K
K
Department of Psychiatry, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Gheldof
M
M
Enzlin
P
P
Timmerman
D
D
Deprest
J
J
Bourne
T
T
Vergote
I
I
D000223:Adaptation, Psychological; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001294:Attitude to Health; D001943:Breast Neoplasms / Q000188:drug therapy / Q000523:psychology*; D016903:Drug Monitoring / Q000523:psychology*; D004717:Endometrium / Q000000981:diagnostic imaging* / Q000187:drug effects; D019160:Endosonography / Q000523:psychology; D005260:Female; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance; D017698:Postmenopause; D020377:Self Efficacy; D013629:Tamoxifen / Q000627:therapeutic use*; D014591:Uterine Diseases / Q000139:chemically induced / Q000517:prevention & control
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen